Negotiations are ongoing in New York to agree the latest UN political declaration on non-communicable diseases (NCDs) and ...

It was by far the most difficult phone call of my life. Absolutely nothing can prepare you for telling your mother that she ...

The relationship between hormone therapy (oestrogen with or without progestogen) and breast cancer risk has been widely ...

We read with great interest the published results of the RADIOSA trial by Giulia Marvaso and colleagues.1 This well designed ...

We read with great interest the Lancet Oncology Editorial1 calling for a coordinated global approach to address the growing ...

We have witnessed weight loss of 13–15% with the glucagon-like peptide-1 (GLP-1) receptor agonist semaglutide and up to 18–23% with the dual GLP-1/glucose-dependent insulinotropic polypeptide (GIP) ...

In June, 2025, the UK government announced plans to boost science and technology research and development (R&D) in the country, pledging to invest £86 billion in the sector over the next 4 years. The ...

We welcome the Lancet Child & Adolescent Health Commission on the future of neonatology, calling for much needed attention to ...

The Lies We've Been Sold and the Policies That Can Save Us sets out her hope of living to the age of 100 years in good health ...

On May 6, 2025, the Global Initiative For Asthma (GINA) published the 2025 update to their Global Strategy for Asthma ...

The House of Commons has approved the Terminally Ill Adults Bill amid narrowing support and ongoing debate. Jacqui Thornton reports.

Gilead's lenacapavir approval by the US Food and Drug Administration (FDA) marks a milestone in HIV prevention, but experts warn over its expense. Sophie Cousins reports.